Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P534. Endoscopic balloon dilatation and/or intensification of medical therapy can achieve and maintain remission in patients with symptomatic intestinal strictures of Crohn's disease
Authors:

K. Papamichael1, E. Archavlis1, N. Kyriakos1, I. Drougas1, D. Tsironikos1, X. Tzanetakou1, I. Internos1, S. Anastasiadis1, P. Karatzas1, G. Mantzaris1, 1Evangelismos Hospital, Athens Greece, A' Department of Gastroenterology, Athens, Greece

P534

Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: a randomized, double-blinded, placebo-controlled multicenter trial

Authors:

H. Tamaki*1, M. Shibatoge1, H. Nakase2

1Takamatsu Red Cross Hospital, Gastroenterology, Takamatsu, Japan, 2Kyoto university, Gastroenterology and Hepatology, Kyoto, Japan

P535.

Clinical predictors of immunomodulation and phenotype progression in Crohn's disease

Authors:

E. Rodrigues-Pinto, F. Magro, R. Coelho, P. Andrade, J. Santos-Antunes, S. Lopes, G. Macedo, Centro Hospitalar São João, Gastroenterology Department, Porto, Portugal

P535. Efficacy of oral supplementation in B12 deficiency in Crohn's disease
Authors:

A. Mir1, M. Gracia1, M. Garcia2, A. Lué3, F. Muñoz2, S. Garcia1, R. Vicente4, F. Gomollón3, 1Hospital Universitario Miguel Servet, Aparato Digestivo, Zaragoza, Spain, 2Complejo Asistencial de León, Aparato Digestivo, León, Spain, 3Hospital Clínico Universitario Lozano Blesa, Aparato Digestivo, Zaragoza, Spain, 4Hospital de Alcañiz, Aparato Digestivo, Alcañiz, Spain

P535

Transition in adolescents with IBD: study of a measuring instrument for transfer readiness

Authors:

G. van den Brink*1, M. van Gaalen1, M. Zijlstra1, C. van der Woude2, J. Escher1

1Erasmus MC-Sophia Children's Hospital, Pediatric Gastroenterology, Rotterdam, Netherlands, 2Erasmus MC, Gastroenterology Unit, Rotterdam, Netherlands

P536.

Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease

Authors:

C. Steenholdt1, K. Bendtzen2, J. Brynskov1, O.Ø. Thomsen1, M.A. Ainsworth1, 1Herlev University Hospital, Department of Gastroenterology, Herlev, Denmark, 2Rigshospitalet, University Hospital of Copenhagen, Institute for Inflammation Research, Copenhagen, Denmark

P536. Effectiveness of the available therapeutic options in the treatment of perianal fistulas in patients with Crohn's disease (CD)
Authors:

B. Arberas-Diez1, M. Chaparro1, P. Burgueño1, I. Vera2, F. Bermejo3, I. Marín-Jiménez4, C. Yela5, P. López6, M.D. Martín7, C. Taxonera8, B. Botella9, R. Pajares10, A. Ponferrada11, M. Calvo2, A. Algaba3, L. Pérez4, B. Casis5, J. Maté1, J.P. Gisbert1, 1Hospital Universitario de La Princesa, IP, Gastroenterology and CIBEREHD, Madrid, Spain, 2Hospital Universitario Puerta de Hierro Majadahonda, Gastroenterology, Madrid, Spain, 3Hospital Universitario de Fuenlabrada, Gastroenterology, Madrid, Spain, 4Hospital Universitario Gregorio Marañón, Gastroenterology, Madrid, Spain, 5Hospital Universitario 12 de Octubre, Gastroenterology, Madrid, Spain, 6Hospital Universitario Fundación Alcorcón, Gastroenterology, Madrid, Spain, 7Hospital Universitario La Paz, Gastroenterology, Madrid, South Korea, 8Hospital Universitario Clínico San Carlos, Gastroenterology, Madrid, Spain, 9Hospital Universitario Infanta Cristina, Gastroenterology, Madrid, Spain, 10Hospital Universitario Infanta Sofia, Gastroenterology, Madrid, Spain, 11Hospital Unviersitario Infanta Leonor, Gastroenterology, Madrid, Spain

P536

Long term efficacy and safety for Sequential Rescue Treatments in patents with steroid refractory Ulcerative Colitis - Two years follow up data

Authors:

M. Protic*1, P. Frei2, C. Manser3, T. Knezevic1, C. Mottet4, P. Juillerat5, S. Markovic1, C. Beglinger6, N. Jojic1, S. Vavricka7, G. Rogler3, F. Seibold8

1University Hospital Zvezdara, Department of Gastroenterology, Belgrade, Serbia, 2See Spital, Department of Gastroenterology, Zürich, Switzerland, 3University Hospital Zurich, Department of Gastroenterology, Zurich, Switzerland, 4Hospital Neuchâtel, Department of Gastroenterology, Neuchâtel, Switzerland, 5University Hospital Bern, Gastroenterology and Hepatology, Bern, Switzerland, 6University Hospital Basel , Division of Gastroenterology & Hepatology, Basel, Switzerland, 7Stadtspital Triemli, Department of Gastroenterology, Zürich, Switzerland, 8Tiefenau Spital, Department of Gastroenterology, Bern, Switzerland

P537.

Clinical factors of anastomotic recurrence revealed in patients with Crohn's disease at double-balloon enteroscopy

Authors:

T. Yamamura1, M. Nakamura1, K. Yamada1, A. Nagura2, T. Yoshimura1, A. Nakano1, H. Oshima1, K. Hurukawa2, K. Funasaka2, E. Ohno2, R. Miyahara1, H. Kawashima1, A. Itoh1, Y. Hirooka2, O. Watanabe1, T. Ando1, N. Ohmiya3, H. Goto1,2, 1Nagoya University, Gastroentorology and Hepatology, Nagoya, Japan, 2Nagoya University Hospital, Endoscopy, Nagoya, Japan, 3Fujita Health University School of Medicine, Gastroentorology, Toyoake, Japan

P537. Early predictors of long term clinical response to adalimumab in Crohn's disease
Authors:

M. Martinato1, T. Slongo1, M. Piovanello2, M. Rigato2, A. Ugoni2, I. Frankovic1, R. Caccaro1, G.C. Sturniolo1, R. D'Incà1, 1Università degli Studi di Padova, Padova, Italy, 2Azienda Ospedaliera di Padova, Padova, Italy

P537

The effect of anti TNF induction therapy on body composition parameters in inflammatory bowel disease

Authors:

A.A. Csontos*1, A. Molnar2, I. Kovacs3, Z. Piri1, B. Katona1, K. Mullner1, P. Miheller1

1Semmelweis University, 2nd Dept. Med., Budapest, Hungary, 2Hungarian Crohn and Colitis Association, Hungarian Crohn and Colitis Association, Budapest, Hungary, 3Hungarian Dietetic Association, Hungarian Dietetic Association, Budapest, Hungary

P538.

Clinical and endoscopic recurrence after surgical resection in patients with Crohn's disease

Authors:

Y.W. Lee1, K.-M. Lee1, W.C. Chung1, C.N. Paik1, H.J. Sung1, Y.S. Oh1, S.H. Jung2, 1St. Vincent's Hospital, The Catholic University of Korea, Internal Medicine, Suwon, South Korea, 2St. Paul's Hospital, The Catholic University of Korea, Internal Medicine, Seoul, South Korea

P538. Duration of remission with exclusive enteral nutrition in Crohn's disease
Authors:

F. Flor-de-Lima1, J. Cardoso1, R. Marques1, M. Tavares1, E. Trindade1, J. Amil-Dias1, 1Unit of Pediatric Gastroenterology, Centro Hospitalar de São João, Porto, Portugal

P538

Pooled safety analysis of long-term, once-daily multimatrix mesalazine use

Authors:

S. Da Silva Sanchez*1, H. Wan2, P. Streck3, D. Willshire4, J.B. Raskin5

1Shire, Medical Affairs, Brussels, Belgium, 2Shire, Biostatistics, Wayne, PA, United States, 3Shire, Global Clinical Development, Wayne, PA, United States, 4Shire, Medical Affairs, North Ryde, Australia, 5University of Miami Health System, Gastroenterology and Internal Medicine, Miami, FL, United States

P539.

Clinical response and mucosal healing after infliximab rescue therapy for patients with severe ulcerative colitis refractory to systemic corticosteroids

Authors:

M. Fortuna1, R. Montanari1, A. Geccherle1, G. Ruffo2, M. Chiaramonte1, 1Sacro Cuore Don Calabria Negrar Hospital, Multispecialistic Centre for Recto-Perineal Diseases (IBD Unit), Department of Gastroenterology, Negrar (VR), Italy, 2Sacro Cuore Don Calabria Negrar Hospital, Department of General Surgery, Negrar – VR, Italy

P539. Dose intensification with anti-TNF agents in inflammatory bowel disease – a secondary care experience
Authors:

G. Kothegal Marimahadevappa1, J.K. Limdi1, 1The Pennine Acute Hospitals NHS Trust, Gastroenterology, Manchester, United Kingdom

P539

Outcome of acute severe ulcerative colitis in patients previously exposed to immunosoppressive therapy

Authors:

S. Deiana*, S. Bagnoli, T. Gabbani, A.L. Inghilesi, N. Manetti, V. Annese

AOU Careggi, SOD Gastroenterologia 2, Firenze, Italy

P540.

Can we predict response to cyclosporine as second line therapy in patients with severe acute colitis of inflammatory bowel disease?

Authors:

N. Ben Mustapha, A. Labidi, M. Serghini, H. Dabbabi, M. Fekih, J. Boubaker, A. Filali, La Rabta Hospital, Gastroenterology A, Tunis, Tunisia

P540. Does the time of ileocoecal resection have an influence on post operative recurrence?
Authors:

M. Fekih1, B. Ben Slimène1, A. Laabidi1, M. Serghini1, N. Ben Mustapha2, J. Boubaker1, L. Kallel1, A. Filali1, 1La Rabta hospital; Tunis El Manar university, Gastro enterology “A”, Tunis, Tunisia, 2La Rabta Hospital, Gastro A Unit, Tunis, Tunisia

P540

Efficacy and safety of infliximab's biosimilar (REMSIMA) for IBD

Authors:

J. Yoon Suk*1, D.I. Park2, Y.H. Kim3, P.J. Seo4, J.W. Kim5, H.W. Kang6

1Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine , Department of Internal Medicine, Seoul, Korea, Republic of, 2Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Department of Internal Medicine, Seoul, Korea, Republic of, 3Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Internal Medicine, Seoul, Korea, Republic of, 4Seoul Song Do Colorectal Hospital, Digestive Endoscopic Center, Seoul, Korea, Republic of, 5Seoul National University Boramae Hospital, Department of Internal Medicine, Seoul, Korea, Republic of, 6College of Medicine, Dongguk University Ilsan Hospital , Department of Internal Medicine, Goyang, Korea, Republic of